Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
Sep 29, 2022, 15:45 ET Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported by Breakthrough Science CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin …
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference Read More »